Oculis Holding AG (OCS) Accumulated Depreciation & Amortization (2023)
Quarterly Accumulated Depreciation & Amortization changed N/A to $444177.7 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $444177.7 through Dec 2023, changed N/A year-over-year, with the annual reading at $444177.7 for FY2023, N/A changed from the prior year.
Oculis Holding AG's Accumulated Depreciation & Amortization history spans 1 years, with the latest figure at $444177.7 for Q4 2023.
- Accumulated Depreciation & Amortization came in at $444177.7 for Q4 2023.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $444177.7 in Q4 2023 to a low of $444177.7 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 444,177.66 |
| Dec 31, 2023 | 444,177.66 |